Nazifa Banu is a Nephrology physician. OpenAlex indexes 11 publications with 394 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
246 Hamburg Tpke
Suite#207
Wayne, NJ 074702156
Telephone
973-653-3366Registry record last updated 21 Jul 2008.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Travere Therapeutics, Inc.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
46%Calcium channel blocker9.8%Amlodipine Besylate75%Nifedipine Er25%Part D≥62 patientsStatin7.8%Rosuvastatin Calcium42%Atorvastatin Calcium41%Simvastatin11%Pravastatin Sodium7%Part D<11 patients+ 13 more classes in this area
Metabolism & gastrointestinal
32.4%Vitamin D3 Analog16.6%Calcitriol100%Part D≥124 patientsSGLT2 inhibitor3.5%Farxiga87%Jardiance13%Part D<11 patients+ 10 more classes in this area
Musculoskeletal
5.4%Xanthine oxidase inhibitor5.4%Allopurinol83%Febuxostat17%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways
Biochemical and Biophysical Research Communications
2007 - Semaphorin 3C regulates endothelial cell function by increasing integrin activity
The FASEB Journal
2006
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”